
XRP jumped 56.3% in a week, outstripping gains from other major tokens. The rally boosted its market capitalization by around $16.2 billion within 24 hours.
The target implies roughly $176B of market value at current circulating supply.
Cash-flow expectations firm. BP’s balance-sheet sensitivity keeps relative momentum intact.
Shares digest a 5.09% week. Peer-relative performance becomes the cleaner signal.
Brent reverses. BP’s higher commodity torque becomes a downside amplifier.
Watch for bargaining dates, a member survey and any change to Boeing’s contingency plan.
| Q2 metric | 2026 | YoY |
|---|---|---|
| Revenue | $108.5M | +89% |
| Adjusted EBITDA | $28.5M | +$41.0M |
| NdPr production | 840 MT | +41% |
| NdPr sales | 1,006 MT | +127% |
| REO production | 11,072 MT | -16% |
| Measure | Value | Vs. close |
|---|---|---|
| Low target | $58.00 | -3.4% |
| Average target | $75.38 | +25.5% |
| Median target | $75.00 | +24.9% |
| High target | $100.00 | +66.5% |
| Consensus | Strong Buy | 18 analysts |
Friday's 9.14% rebound left MP only 2.26% higher for the week. The operating case is improving, but the earnings bridge remains policy-sensitive: Q2 price-protection income equaled nearly two-thirds of adjusted EBITDA.
Rare-earth trade policy
Independence magnet qualification
10X construction progress
Follow-through after high-volume rally
Sources: Nasdaq market data; MP Materials Q2 2026 results; S&P Global analyst data via StockAnalysis, last updated August 19, 2026. Adjusted EBITDA is non-GAAP. Percentages are calculated from reported figures and may vary slightly due to rounding.
Dogecoin led Bitcoin over the past week, while Coinbase finished Friday 25.6% above its August 14 close. The next signal is turnover: lasting volume can help transaction revenue; a fast price reversal cannot.
| Operating marker | Q2 2026 | Read-through |
|---|---|---|
| Transaction revenue | -21% q/q | Trading softness was visible |
| Trading-volume share | 10.3% | Record; up from 9.1% |
| Subscription/services mix | 48% of net revenue | Buffers fee volatility |
| Adjusted EBITDA | 14th positive quarter | Cost discipline held |
| Buy / Hold / Sell | 22 / 9 / 3 |
|---|---|
| Consensus | Buy |
| Average target | $195.52 · 4.8% above close |
| Median target | $185.00 · 0.8% below close |
| Low / High | $95 / $330 |
NASDAQ: AAOI · Investor snapshot
Applied Optoelectronics, Inc. · U.S. market closed Friday, August 21, 2026
-3.32% Friday
Closed August 21 at 4:00 p.m. EDT.
-9.83% vs. close
Nasdaq last sale at 6:25 p.m. EDT. Extended-hours prices can be thin.
Raymond James and Needham may sell shares over time. AOI is not required to use it.
2% sales commissionAt Friday's close, equal to 5.7% of the 84.91 million shares outstanding on August 20.
The balance sheet is liquid, but capacity expansion consumes cash quickly. The new authorization is 1.18× June cash plus restricted cash.
Midpoint implies 42.0% sequential growth. Management says demand may exceed capacity through mid-2027.
Consensus: Buy from six analysts. Three were Holds. Targets were last updated before the ATM filing.
The SEC illustration is mechanical, not a forecast. Actual prices and issued shares will vary.
Equity funds the 800G and 1.6T ramp. Q3 revenue reaches or exceeds the $272.5 million midpoint.
AOI sells gradually. Investors weigh added capacity against a persistent supply overhang.
Weak pricing forces more shares into the market while production delays or customer timing slow the ramp.
Sources: August 21 Form 8-K, prospectus supplement, Q2 Form 10-Q, company Q2 release, S&P Global analyst data via StockAnalysis, and Nasdaq market data. Calculations use displayed figures and may differ due to rounding.
Market data as of August 21, 2026, 16:00 EDT
| View | Rating | Target | Upside |
|---|---|---|---|
| Freedom | Hold | $8 | 12.5% |
| S&P consensus | Hold | $13 | 82.8% |
| Cantor | Spec. Buy | $18 | 153.2% |
Moderna · NASDAQ:MRNA
Day range $132.42–$159.47 · Volume 86.74M vs. 15.08M average
$62.96 before the readout to $145.13 Friday.
$82.17 per share × 399.24M shares.
About 8.4× June cash and investments.
Before the $950M litigation payment made in July.
INTerpath-001 enrolled 1,137 melanoma patients and met recurrence-free and distant-metastasis-free survival endpoints. No new safety signal emerged. The full Phase 3 hazard ratios, confidence intervals, subgroup results and overall-survival data remain undisclosed. Investors have added $32.81 billion of equity value without the effect size.
Risk: the price can reverse if detailed efficacy, safety or regulatory timing falls short of the expectations embedded in the rally.
Sources: Google Finance · Phase 3 release · SEC Q2 filing
| Q2 net loss | $9.6M |
| Q2 R&D | $6.3M |
| Cash / share | $0.68 |
| Shares outstanding | 201.9M |
| Share-count growth | +31.9% |
Rivian Automotive · NASDAQ:RIVN
Session range $16.06–$17.15 · Volume 29.89M vs. 24.89M average
Nearly equal to July's net equity proceeds.
Net proceeds from 86.25M shares at $15.50.
The follow-on discount has been repaired.
$7.163B pro forma liquidity ÷ Q2 free-cash outflow.
Rivian's rally repaired the dilution discount, but it also carried the stock to Wall Street's average target. The next rerating needs operating proof: R2 volume, better automotive gross margin and tighter cash use. Three months of free Adventure Network charging, a $3,000 lease contribution and discounted financing may pull R1 deliveries into Q3. They also test pricing power.
Runway is a static comparison, not company guidance. Options-led moves can reverse. Incentives, R2 delays or higher working capital could pressure margins and liquidity.
Sources: Google Finance · Rivian Q2 release · Rivian offers
| Revenue | $74.9M |
| Net loss | $177.1M |
| Adjusted EBITDA* | $10.4M |
| Project financing | $7.5B |
| Consolidated debt | $7.6B |
Targeted Serra Verde closing and leadership handoff preparation.
Stillwater targets 600 tonnes annual magnet run rate; Round Top feasibility work due.
Round Top definitive feasibility study targeted for publication.
Blacksburg commissioning and Round Top commercial-production targets.
Headline book value does not flow cleanly to common shareholders.
| Measure | Q2 2026 | Q1 2026 |
|---|---|---|
| Net income | $4.0B | $3.7B |
| Net revenue | $7.6B | $7.3B |
| Credit-loss provision | $485M | $277M |
| Non-interest expense | $2.1B | $2.2B |
| Net worth | $116.5B | $112.5B |
| Firm | View | Target |
|---|---|---|
| B. Riley | Neutral | $7.00 |
| Wedbush | Neutral | $8.00 |
| KBW | Underperform | $8.50 |
| BTIG | Buy | $20.00 |
| 7-analyst aggregate | Hold | $12.25 |
| Metric | Old | Updated |
|---|---|---|
| Q2 revenue | $12.6M | $13.5M |
| Revenue growth | 116% | 157% |
| GAAP op. loss | $30.6M | $29.9M |
| FY revenue guide | $43.0M | $45.1M |
| 2026 target | 30 logical qubits |
| Illinois system | 2027 deployment |
| Commerce LOI | Up to $100M |
| New headquarters | ~107,000 sq. ft. |
Market data: August 21, 2026, 12:33 p.m. EDT (18:33 CEST), during the U.S. session. USD unless marked CAD.
Estimated equity value added Friday. It equals 99.7% of Denison’s $345 million convertible-note principal. The difference is about $1.02 million.
Four-peer average: +7.83%. DNN outperformance: 4.43 percentage points.
S&P Global average target from 14 analysts, last updated July 13. Implied upside from $3.52: 41.8%.
Canadian actions: RBC Outperform, C$6.00; National Bank Outperform, C$6.50; TD Buy, C$6.50.
Sources: Google Finance, Denison Q2 results, Phoenix construction update, convertible-note terms, and S&P Global consensus via StockAnalysis. Analyst targets are forecasts, not guarantees.
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $16.1B | $12.9B | +25% |
| Non-GAAP gross margin | 41.8% | 29.7% | +12.1 pts |
| Non-GAAP operating margin | 17.2% | −3.9% | +21.1 pts |
| Non-GAAP EPS | $0.42 | −$0.10 | Positive |
| Operating cash flow | $7.0B | — | Net raise = 2.8× |
The product is faster. The harder test is whether Nike can turn 18% more energy return into full-price sales while a major retailer reports a 6.8% North American decline.
*Includes about 900 basis points from expected IEEPA tariff recovery.
Pegasus Plus 2 must work in both partner stores and Nike's owned channels.
JD Sports Q2 like-for-like sales, 13 weeks ended Aug. 1, 2026.
39-analyst July consensus. JPMorgan moved to Underweight with a $40 target on Aug. 4.
Today’s highest-ranked model selections.